{"id":"W2169787227","doi":"10.1111/j.1365-2133.2006.07344.x","title":"CLinical experience acquired with the efalizumab (Raptiva<sup>®</sup>) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial","year":2006,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":143,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Efalizumab; Plaque psoriasis; Psoriasis; Placebo; Medicine; Randomized controlled trial; Clinical trial; Internal medicine; Dermatology; Alternative medicine; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008591064,0.0003693985,0.002092614,0.0002410293,0.0002341892,0.0001007327,0.0006088612,0.0004463759,0.0001663308],"category_scores_gemma":[0.0005627011,0.0002470578,0.0004293883,0.0001881173,0.0004567748,0.0002949314,0.00007118979,0.0004585881,0.00002398483],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007614113,"about_ca_system_score_gemma":0.0003129631,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004233514,"about_ca_topic_score_gemma":0.0002964853,"domain_scores_codex":[0.9938778,0.00264854,0.002249834,0.0005022626,0.0002324127,0.0004891969],"domain_scores_gemma":[0.9958913,0.002148075,0.001273237,0.0002764252,0.0003331976,0.00007780072],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9850542,0.002384717,0.0004989207,0.000001330462,0.00159094,0.0008684023,0.0008828568,0.0002504578,0.000009469843,0.0000296676,0.002750984,0.005678038],"study_design_scores_gemma":[0.9929559,0.002041864,0.0005784842,0.0001484072,0.0004555279,0.001894735,0.0004165597,0.00006773863,0.0001318611,0.00005716176,0.0009569766,0.0002947578],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9931148,0.0006670333,0.0003792081,0.0007965499,0.00152963,0.003016956,0.0002137111,0.00002542101,0.0002567369],"genre_scores_gemma":[0.998212,0.0001246837,0.0002594554,0.0001792753,0.0004244082,0.0003220746,0.000253251,0.00003128371,0.0001935131],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00790171,"threshold_uncertainty_score":0.9999982,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01187332646217483,"score_gpt":0.2591450540354009,"score_spread":0.2472717275732261,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}